We've upgraded AI Tools on TaxTMI with two powerful modes:
1. Basic • Quick overview summary answering your query with references• Category-wise results to explore all relevant documents on TaxTMI
2. Advanced • Includes everything in Basic • Detailed report covering: - Overview Summary - Governing Provisions [Acts, Notifications, Circulars] - Relevant Case Laws - Tariff / Classification / HSN - Expert views from TaxTMI - Practical Guidance with immediate steps and dispute strategy
• Also highlights how each document is relevant to your query, helping you quickly understand key insights without reading the full text.Help Us Improve - by giving the rating with each AI Result:
Tribunal Affirms Unabsorbed Capital Expenditure as Depreciation, Eligible for Carry Forward Under Sections 32(2) and 72A(4) The Tribunal dismissed the revenue's appeal, affirming the CIT(A)'s decision that unabsorbed capital expenditure on scientific research of the demerged ...
Cases where this provision is explicitly mentioned in the judgment/order text; may not be exhaustive. To view the complete list of cases mentioning this section, Click here.
Provisions expressly mentioned in the judgment/order text.
Tribunal Affirms Unabsorbed Capital Expenditure as Depreciation, Eligible for Carry Forward Under Sections 32(2) and 72A(4)
The Tribunal dismissed the revenue's appeal, affirming the CIT(A)'s decision that unabsorbed capital expenditure on scientific research of the demerged company should be treated as unabsorbed depreciation under section 32(2) and thus eligible for carry forward under section 72A(4) of the Income-tax Act. The Tribunal held that section 35(4) allows the treatment of such expenditures similarly to depreciation, supporting the assessee's position that demergers should be tax neutral. Consequently, the unabsorbed capital expenditure on scientific research is eligible for carry forward as unabsorbed depreciation.
Issues Involved:
1. Whether the unabsorbed capital expenditure on scientific research of the demerged company can be treated as accumulated loss/depreciation loss u/s 32(2) and carried forward u/s 72A(4) of the Income-tax Act.
Summary:
Issue 1: Treatment of Unabsorbed Capital Expenditure on Scientific Research
The appeal by the revenue challenges the CIT(A)'s order allowing the claim of unabsorbed loss on capital expenditure on scientific research and development of the demerged company, treating it as accumulated loss/depreciation loss u/s 32(2) and thus eligible for carry forward u/s 72A(4) of the Income-tax Act.
The demerger of M/s. Maharashtra Hybrid Seeds Co. Ltd. resulted in the creation of M/s. Mahyco Vegetable Seeds Ltd. The unabsorbed depreciation and capital expenditure on scientific research were distributed between the demerged and resulting companies based on the ratio of asset division. The Assessing Officer allowed the benefit of section 72A(4) for unabsorbed depreciation but denied it for unabsorbed capital expenditure on scientific research.
The CIT(A) held that the assessee was entitled to carry forward the claim of unabsorbed scientific research expenditure u/s 72A(4). The revenue argued that section 35(4) could not be equated with section 32(2) as they are distinct, and unabsorbed capital expenditure on scientific research does not fall within the definitions of accumulated loss or unabsorbed depreciation u/s 72A(7).
The assessee contended that demergers should be tax neutral, and the unabsorbed capital expenditure on scientific research should be treated at par with unabsorbed depreciation, citing the Supreme Court's decision in Escorts Ltd. v. Union of India and other judgments.
The Tribunal considered the rival submissions and noted that section 35(4) states that the provisions of section 32(2) apply to deductions allowable under section 35(1)(iv) as they apply to depreciation. The Tribunal held that unabsorbed capital expenditure on scientific research cannot be considered accumulated loss but is treated similarly to unabsorbed depreciation for carry forward purposes.
The Tribunal concluded that the unabsorbed capital expenditure on scientific research should be treated as unabsorbed depreciation for the purposes of section 72A(7) and thus eligible for carry forward. The appeal by the revenue was dismissed.
Full Summary is available for active users!
Note: It is a system-generated summary and is for quick reference only.